Full text
3,740 characters
· extracted from
oa-doi-fallback
· click to expand
Abstract
Analyzing treatment effectiveness from electronic health records (EHR) presents unique challenges in causal inference, particularly when comparing multiple treatment options with high-dimensional covariates. We propose a novel framework combining instrumental variable (IV) analysis with advanced Bayesian feature selection methods and neural networks to estimate causal effects in multi-valued treatment settings. Our approach addresses three key methodological challenges: handling multiple treatment comparisons simultaneously, comparing Bayesian feature selection methods, and selecting relevant features while capturing complex nonlinear relationships in outcome models.
Through extensive simulation studies, we demonstrate that spike-and-slab priors achieve superior performance in treatment effect estimation with the lowest mean absolute bias (0.071) compared to ALL (0.074), LASSO (0.080), and Bayesian LASSO (0.083) methods. The consistency of bias control across treatment pairs demonstrates the robustness of our Bayesian feature selection approach, particularly in identifying clinically relevant predictors.
We apply this framework to compare three commonly used vasopressors (norepinephrine, vasopressin, and phenylephrine) using MIMIC-IV data[1]. Using physician prescribing preferences as instruments[2, 3, 4], our analysis reveals a clear hierarchical pattern in treatment effectiveness. Vasopressin demonstrated superior effectiveness compared to both norepinephrine (ATE = 0.134, 95% CI [0.115, 0.152]) and phenylephrine (ATE = 0.173, 95% CI [0.156, 0.191]), while phenylephrine showed inferior outcomes compared to norepinephrine (ATE = -0.040, 95% CI [-0.048, -0.031]).
Our methodological framework provides a robust approach for analyzing multi-valued treatments in high-dimensional observational data, with broad applications beyond vessopressors in critical care. The integration of instrumental variable analysis, Bayesian feature selection, and advanced modeling techniques offers a promising direction for using EHR data to inform treatment decisions while addressing key challenges in causal inference.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We used simulated data and MIMIC-IV, which is a publicly available database.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.